Efficacy and safety of generic imatinib after switching from original imatinib in patients treated for chronic myeloid leukemia in the United States

INTRODUCTION: Imatinib is standard therapy for patients with chronic myeloid leukemia (CML). In February 2016, a generic formulation entered the US market. Physicians and patients are frequently concerned about whether switching from original to generic drugs may affect the efficacy and/or safety. M...

Descripción completa

Detalles Bibliográficos
Autores principales: Abou Dalle, Iman, Kantarjian, Hagop, Burger, Jan, Estrov, Zeev, Ohanian, Maro, Verstovsek, Srdan, Ravandi, Farhad, Borthakur, Gautam, Garcia‐Manero, Guillermo, Jabbour, Elias, Cortes, Jorge
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2019
Materias:
Clinical Cancer Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6825993/
https://www.ncbi.nlm.nih.gov/pubmed/31502383
http://dx.doi.org/10.1002/cam4.2545

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6825993/
https://www.ncbi.nlm.nih.gov/pubmed/31502383
http://dx.doi.org/10.1002/cam4.2545

Ejemplares similares